O	0	15	Pharmacokinetic	Pharmacokinetic	JJ	B-NP
O	15	16	-	-	HYPH	I-NP
O	16	31	pharmacodynamic	pharmacodynamic	JJ	I-NP
O	32	40	analysis	analysis	NN	I-NP
O	40	41	.	.	.	O

O	42	45	The	The	DT	B-NP
O	46	50	mean	mean	JJ	I-NP
O	51	52	(	(	(	O
O	52	54	90	90	CD	B-NP
O	54	55	%	%	NN	I-NP
O	56	58	CI	CI	NN	I-NP
O	58	59	)	)	)	O
O	60	65	slope	slope	NN	B-NP
O	66	74	estimate	estimate	NN	I-NP
O	75	79	from	from	IN	B-PP
O	80	83	the	the	DT	B-NP
O	84	93	linezolid	linezolid	NN	I-NP
O	94	107	concentration	concentration	NN	I-NP
O	107	108	-	-	HYPH	B-NP
O	108	109	R	R	NN	I-NP
O	109	110	-	-	HYPH	B-NP
O	110	111	R	R	NN	I-NP
O	112	120	interval	interval	NN	I-NP
O	121	129	analysis	analysis	NN	I-NP
O	130	133	was	be	VBD	B-VP
O	134	135	-	-	SYM	B-ADJP
O	135	136	0	0	CD	B-NP
O	136	137	.	.	SYM	I-NP
O	137	141	0017	0017	CD	I-NP
O	142	143	(	(	(	O
O	143	144	-	-	SYM	B-NP
O	144	145	0	0	CD	B-NP
O	145	146	.	.	SYM	I-NP
O	146	150	0022	0022	CD	I-NP
O	151	153	to	to	TO	B-PP
O	154	155	-	-	SYM	B-NP
O	155	156	0	0	CD	I-NP
O	156	157	.	.	SYM	I-NP
O	157	161	0011	0011	CD	I-NP
O	161	162	)	)	)	O
O	163	165	ms	ms	NN	B-NP
O	165	166	/	/	SYM	B-NP
O	166	168	ng	ng	NN	I-NP
O	168	169	/	/	SYM	I-NP
O	169	171	ml	ml	NN	I-NP
O	171	172	.	.	.	O

O	173	177	This	This	DT	B-NP
O	178	188	translates	translate	VBZ	B-VP
O	189	191	to	to	TO	I-VP
O	192	196	mean	mean	VB	I-VP
O	197	198	(	(	(	O
O	198	200	90	90	CD	B-NP
O	200	201	%	%	NN	I-NP
O	202	204	CI	CI	NN	I-NP
O	204	205	)	)	)	O
O	206	215	predicted	predict	VBD	B-VP
O	216	225	decreases	decrease	NNS	B-NP
O	226	228	in	in	IN	B-PP
B-Organ	229	234	heart	heart	NN	B-NP
O	235	239	rate	rate	NN	I-NP
O	240	242	of	of	IN	B-PP
O	243	256	approximately	approximately	RB	B-NP
O	257	258	1	1	CD	I-NP
O	258	259	.	.	.	I-NP
O	259	260	5	5	CD	I-NP
O	261	262	(	(	NN	I-NP
O	262	263	1	1	CD	I-NP
O	263	264	.	.	.	O
O	264	265	0	0	CD	B-NP
O	266	268	to	to	TO	I-NP
O	269	270	2	2	CD	I-NP
O	270	271	.	.	.	I-NP
O	271	272	0	0	CD	I-NP
O	272	273	)	)	)	O
O	274	277	and	and	CC	O
O	278	279	3	3	CD	B-NP
O	279	280	.	.	.	I-NP
O	280	281	0	0	CD	I-NP
O	282	283	(	(	(	O
O	283	284	2	2	CD	B-NP
O	284	285	.	.	.	O
O	285	286	1	1	CD	B-NP
O	287	289	to	to	TO	B-PP
O	290	291	4	4	CD	B-NP
O	291	292	.	.	.	I-NP
O	292	293	1	1	CD	I-NP
O	293	294	)	)	)	O
O	295	300	beats	beat	VBZ	B-VP
O	300	301	/	/	SYM	B-NP
O	301	304	min	min	NN	I-NP
O	305	307	at	at	IN	B-PP
O	308	311	the	the	DT	B-NP
O	312	316	mean	mean	JJ	I-NP
O	317	321	Cmax	Cmax	NN	I-NP
O	322	331	following	follow	VBG	B-PP
O	332	335	the	the	DT	B-NP
O	336	350	administration	administration	NN	I-NP
O	351	353	of	of	IN	B-PP
O	354	357	600	600	CD	B-NP
O	357	358	-	-	HYPH	I-NP
O	359	362	and	and	CC	I-NP
O	363	364	1	1	CD	I-NP
O	364	365	,	,	,	I-NP
O	365	368	200	200	CD	I-NP
O	368	369	-	-	HYPH	I-NP
O	369	371	mg	mg	NN	I-NP
O	372	381	linezolid	linezolid	JJ	I-NP
O	382	387	doses	dose	NNS	I-NP
O	387	388	,	,	,	O
O	389	401	respectively	respectively	RB	B-ADVP
O	401	402	.	.	.	O

O	403	406	The	The	DT	B-NP
O	407	412	study	study	NN	I-NP
O	412	413	-	-	HYPH	O
O	413	421	specific	specific	JJ	B-NP
O	422	426	mean	mean	JJ	I-NP
O	427	437	correction	correction	NN	I-NP
O	438	444	factor	factor	NN	I-NP
O	445	454	estimated	estimate	VBN	B-VP
O	455	459	from	from	IN	B-PP
O	460	468	baseline	baseline	NN	B-NP
O	469	473	data	datum	NNS	I-NP
O	474	477	was	be	VBD	B-VP
O	478	479	0	0	CD	B-NP
O	479	480	.	.	.	I-NP
O	480	483	278	278	CD	I-NP
O	483	484	,	,	,	O
O	485	490	which	which	WDT	B-NP
O	491	493	is	be	VBZ	B-VP
O	494	502	slightly	slightly	RB	B-ADJP
O	503	507	less	less	JJR	I-ADJP
O	508	512	than	than	IN	B-PP
O	513	523	Fridericia	Fridericia	NNP	B-NP
O	523	524	'	'	POS	B-NP
O	524	525	s	s	NN	I-NP
O	526	536	correction	correction	NN	I-NP
O	537	538	(	(	(	O
O	538	539	0	0	CD	B-NP
O	539	540	.	.	.	I-NP
O	540	543	333	333	CD	I-NP
O	543	544	)	)	)	O
O	544	545	.	.	.	O

O	546	556	Evaluation	Evaluation	NN	B-NP
O	557	559	of	of	IN	B-PP
O	560	563	the	the	DT	B-NP
O	564	571	various	various	JJ	I-NP
O	572	582	correction	correction	NN	I-NP
O	583	590	factors	factor	NNS	I-NP
O	591	597	showed	show	VBD	B-VP
O	598	602	that	that	IN	B-SBAR
O	603	607	QTcF	QTcF	NNP	B-NP
O	608	612	most	most	RBS	B-ADVP
O	613	626	appropriately	appropriately	RB	I-ADVP
O	627	635	resolves	resolve	VBZ	B-VP
O	636	639	the	the	DT	B-NP
O	640	652	relationship	relationship	NN	I-NP
O	653	660	between	between	IN	B-PP
O	661	664	the	the	DT	B-NP
O	665	667	QT	QT	NN	I-NP
O	668	676	interval	interval	NN	I-NP
O	677	680	and	and	CC	O
O	681	684	the	the	DT	B-NP
B-Organ	685	690	heart	heart	NN	I-NP
O	691	695	rate	rate	NN	I-NP
O	696	698	in	in	IN	B-PP
O	699	702	the	the	DT	B-NP
O	703	711	baseline	baseline	NN	I-NP
O	712	716	data	datum	NNS	I-NP
O	717	721	from	from	IN	B-PP
O	722	725	the	the	DT	B-NP
O	726	733	present	present	JJ	I-NP
O	734	739	study	study	NN	I-NP
O	739	740	.	.	.	O

O	741	745	This	This	DT	B-NP
O	746	748	is	be	VBZ	B-VP
O	749	756	evident	evident	JJ	B-ADJP
O	757	761	upon	upon	IN	B-PP
O	762	772	inspection	inspection	NN	B-NP
O	773	775	of	of	IN	B-PP
O	776	779	Fig	Fig	NNP	B-NP
O	779	780	.	.	.	O

O	781	782	4	4	CD	B-NP
O	782	783	,	,	,	O
O	784	789	since	since	IN	B-SBAR
O	790	793	the	the	DT	B-NP
O	794	799	slope	slope	NN	I-NP
O	800	807	between	between	IN	B-PP
O	808	811	the	the	DT	B-NP
O	812	816	QTcF	QTcF	NN	I-NP
O	817	825	interval	interval	NN	I-NP
O	826	829	and	and	CC	O
O	830	833	the	the	DT	B-NP
O	834	835	R	R	NN	I-NP
O	835	836	-	-	HYPH	B-NP
O	836	837	R	R	NN	I-NP
O	838	846	interval	interval	NN	I-NP
O	847	849	is	be	VBZ	B-VP
O	850	857	closest	close	JJS	B-ADJP
O	858	860	to	to	TO	B-PP
O	861	865	zero	zero	CD	B-NP
O	866	870	when	when	WRB	B-ADVP
O	871	875	this	this	DT	B-NP
O	876	886	correction	correction	NN	I-NP
O	887	889	is	be	VBZ	B-VP
O	890	897	applied	apply	VBN	I-VP
O	897	898	.	.	.	O

O	899	902	Fig	Fig	NNP	B-NP
O	902	903	.	.	.	O

O	904	905	4	4	LS	B-LST
O	905	906	.	.	.	O

O	907	917	Evaluation	Evaluation	NN	B-NP
O	918	920	of	of	IN	B-PP
O	921	928	various	various	JJ	B-NP
B-Organ	929	934	heart	heart	NN	I-NP
O	935	939	rate	rate	NN	I-NP
O	940	950	correction	correction	NN	I-NP
O	951	958	factors	factor	NNS	I-NP
O	959	962	for	for	IN	B-PP
O	963	966	the	the	DT	B-NP
O	967	969	QT	QT	NN	I-NP
O	970	978	interval	interval	NN	I-NP
O	979	985	versus	versus	IN	B-PP
O	986	989	the	the	DT	B-NP
O	990	991	R	R	NN	I-NP
O	991	992	-	-	HYPH	B-NP
O	992	993	R	R	NN	I-NP
O	994	1002	interval	interval	NN	I-NP
O	1002	1003	.	.	.	O

O	1004	1007	The	The	DT	B-NP
O	1008	1017	predicted	predict	VBN	I-NP
O	1018	1022	line	line	NN	I-NP
O	1023	1025	in	in	IN	B-PP
O	1026	1030	each	each	DT	B-NP
O	1031	1037	figure	figure	NN	I-NP
O	1038	1048	represents	represent	VBZ	B-VP
O	1049	1052	the	the	DT	B-NP
O	1053	1056	fit	fit	NN	I-NP
O	1057	1061	from	from	IN	B-PP
O	1062	1063	a	a	DT	B-NP
O	1064	1070	linear	linear	JJ	I-NP
O	1071	1076	mixed	mix	VBN	I-NP
O	1076	1077	-	-	HYPH	I-NP
O	1077	1083	effect	effect	NN	I-NP
O	1084	1089	model	model	NN	I-NP
O	1090	1094	with	with	IN	B-PP
O	1095	1096	R	R	NN	B-NP
O	1096	1097	-	-	HYPH	I-NP
O	1097	1098	R	R	NN	I-NP
O	1099	1107	interval	interval	NN	I-NP
O	1108	1110	as	as	IN	B-PP
O	1111	1112	a	a	DT	B-NP
O	1113	1118	fixed	fix	VBN	I-NP
O	1119	1125	effect	effect	NN	I-NP
O	1126	1129	and	and	CC	I-NP
O	1130	1137	subject	subject	NN	I-NP
O	1137	1138	-	-	HYPH	O
O	1138	1146	specific	specific	JJ	B-NP
O	1147	1153	random	random	JJ	I-NP
O	1154	1161	effects	effect	NNS	I-NP
O	1162	1165	for	for	IN	B-PP
O	1166	1175	intercept	intercept	NN	B-NP
O	1176	1179	and	and	CC	I-NP
O	1180	1185	slope	slope	NN	I-NP
O	1185	1186	.	.	.	O

O	1187	1190	The	The	DT	B-NP
O	1191	1198	results	result	NNS	I-NP
O	1199	1203	from	from	IN	B-PP
O	1204	1207	the	the	DT	B-NP
O	1208	1221	concentration	concentration	NN	I-NP
O	1221	1222	-	-	HYPH	B-NP
O	1222	1226	QTcF	QTcF	NN	I-NP
O	1227	1235	analysis	analysis	NN	I-NP
O	1236	1239	are	be	VBP	B-VP
O	1240	1251	graphically	graphically	RB	I-VP
O	1252	1260	depicted	depict	VBN	I-VP
O	1261	1263	in	in	IN	B-PP
O	1264	1267	Fig	Fig	NNP	B-NP
O	1267	1268	.	.	.	O

O	1269	1270	5	5	LS	B-LST
O	1270	1271	.	.	.	O

O	1272	1275	The	The	DT	B-NP
O	1276	1280	mean	mean	JJ	I-NP
O	1281	1282	(	(	(	O
O	1282	1284	90	90	CD	B-NP
O	1284	1285	%	%	NN	I-NP
O	1286	1288	CI	CI	NN	I-NP
O	1288	1289	)	)	)	O
O	1290	1295	slope	slope	NN	B-NP
O	1296	1304	estimate	estimate	NN	I-NP
O	1305	1309	from	from	IN	B-PP
O	1310	1313	the	the	DT	B-NP
O	1314	1323	linezolid	linezolid	NN	I-NP
O	1324	1337	concentration	concentration	NN	I-NP
O	1337	1338	-	-	HYPH	B-NP
O	1338	1342	QTcF	QTcF	NN	I-NP
O	1343	1351	analysis	analysis	NN	I-NP
O	1352	1355	was	be	VBD	B-VP
O	1356	1357	-	-	SYM	B-ADJP
O	1357	1358	0	0	CD	B-NP
O	1358	1359	.	.	SYM	I-NP
O	1359	1363	0145	0145	CD	I-NP
O	1364	1365	(	(	(	O
O	1365	1366	-	-	SYM	B-NP
O	1366	1367	0	0	CD	B-NP
O	1367	1368	.	.	SYM	I-NP
O	1368	1372	0768	0768	CD	I-NP
O	1373	1375	to	to	TO	B-PP
O	1376	1377	0	0	CD	B-NP
O	1377	1378	.	.	.	O
O	1378	1382	0477	0477	CD	O
O	1382	1383	)	)	)	O
O	1384	1386	ms	ms	NN	B-NP
O	1386	1387	/	/	SYM	B-NP
O	1387	1390	mug	mug	NN	I-NP
O	1390	1391	/	/	SYM	I-NP
O	1391	1393	ml	ml	NN	I-NP
O	1393	1394	.	.	.	O

O	1395	1397	At	At	IN	B-PP
O	1398	1401	the	the	DT	B-NP
O	1402	1411	geometric	geometric	JJ	I-NP
O	1412	1416	mean	mean	JJ	I-NP
O	1417	1421	Cmax	Cmax	NN	I-NP
O	1422	1431	following	follow	VBG	B-PP
O	1432	1435	the	the	DT	B-NP
O	1436	1444	infusion	infusion	NN	I-NP
O	1445	1447	of	of	IN	B-PP
O	1448	1457	linezolid	linezolid	NN	B-NP
O	1458	1460	at	at	IN	B-PP
O	1461	1464	600	600	CD	B-NP
O	1465	1467	mg	mg	NN	I-NP
O	1468	1469	(	(	(	O
O	1469	1471	14	14	CD	B-NP
O	1471	1472	.	.	.	O
O	1472	1473	9	9	CD	B-NP
O	1474	1477	mug	mug	NN	I-NP
O	1477	1478	/	/	SYM	B-NP
O	1478	1480	ml	ml	NN	I-NP
O	1480	1481	)	)	)	O
O	1482	1485	and	and	CC	O
O	1486	1487	1	1	CD	B-NP
O	1487	1488	,	,	,	O
O	1488	1491	200	200	CD	B-NP
O	1492	1494	mg	mg	NN	I-NP
O	1495	1496	(	(	(	O
O	1496	1498	30	30	CD	B-NP
O	1498	1499	.	.	.	O
O	1499	1500	5	5	CD	B-NP
O	1501	1504	mug	mug	NN	I-NP
O	1504	1505	/	/	SYM	B-NP
O	1505	1507	ml	ml	NN	I-NP
O	1507	1508	)	)	)	O
O	1508	1509	,	,	,	O
O	1510	1513	the	the	DT	B-NP
O	1514	1518	mean	mean	JJ	I-NP
O	1519	1520	(	(	(	O
O	1520	1522	90	90	CD	B-NP
O	1522	1523	%	%	NN	I-NP
O	1524	1526	CI	CI	NN	I-NP
O	1526	1527	)	)	)	O
O	1528	1537	predicted	predict	VBD	B-VP
O	1538	1545	placebo	placebo	NN	B-NP
O	1545	1546	-	-	HYPH	B-NP
O	1546	1554	adjusted	adjust	VBN	I-NP
O	1555	1562	changes	change	NNS	I-NP
O	1563	1567	from	from	IN	B-PP
O	1568	1571	the	the	DT	B-NP
O	1572	1580	baseline	baseline	NN	I-NP
O	1581	1585	QTcF	QTcF	NN	I-NP
O	1586	1590	were	be	VBD	B-VP
O	1591	1592	-	-	SYM	B-ADJP
O	1592	1593	0	0	CD	B-NP
O	1593	1594	.	.	SYM	I-NP
O	1594	1597	217	217	CD	I-NP
O	1598	1599	(	(	(	O
O	1599	1600	-	-	SYM	B-NP
O	1600	1601	1	1	CD	I-NP
O	1601	1602	.	.	SYM	I-NP
O	1602	1604	14	14	CD	I-NP
O	1605	1607	to	to	TO	I-NP
O	1608	1609	0	0	CD	I-NP
O	1609	1610	.	.	.	I-NP
O	1610	1613	710	710	CD	I-NP
O	1613	1614	)	)	)	O
O	1615	1618	and	and	CC	O
O	1619	1620	-	-	SYM	B-NP
O	1620	1621	0	0	CD	I-NP
O	1621	1622	.	.	SYM	I-NP
O	1622	1625	444	444	CD	I-NP
O	1626	1627	(	(	(	O
O	1627	1628	-	-	SYM	B-NP
O	1628	1629	2	2	CD	I-NP
O	1629	1630	.	.	SYM	I-NP
O	1630	1632	34	34	CD	I-NP
O	1633	1635	to	to	TO	B-PP
O	1636	1637	1	1	CD	B-NP
O	1637	1638	.	.	.	O
O	1638	1640	45	45	CD	O
O	1640	1641	)	)	)	O
O	1642	1644	ms	m	NNS	B-NP
O	1644	1645	,	,	,	O
O	1646	1658	respectively	respectively	RB	B-ADVP
O	1658	1659	,	,	,	O
O	1660	1664	thus	thus	RB	B-ADVP
O	1665	1675	confirming	confirm	VBG	B-VP
O	1676	1677	a	a	DT	B-NP
O	1678	1682	lack	lack	NN	I-NP
O	1683	1685	of	of	IN	B-PP
O	1686	1687	a	a	DT	B-NP
O	1688	1700	relationship	relationship	NN	I-NP
O	1701	1708	between	between	IN	B-PP
O	1709	1718	linezolid	linezolid	JJ	B-NP
O	1719	1733	concentrations	concentration	NNS	I-NP
O	1734	1737	and	and	CC	O
O	1738	1741	QTc	QTc	NN	B-NP
O	1742	1750	interval	interval	NN	I-NP
O	1750	1751	.	.	.	O

O	1752	1755	Fig	Fig	NNP	B-NP
O	1755	1756	.	.	.	O

O	1757	1758	5	5	LS	B-LST
O	1758	1759	.	.	.	O

O	1760	1764	QTcF	QTcF	NN	B-NP
O	1765	1773	interval	interval	NN	I-NP
O	1774	1780	versus	versus	IN	B-PP
B-Organism_substance	1781	1787	plasma	plasma	NN	B-NP
O	1788	1797	linezolid	linezolid	NN	I-NP
O	1798	1812	concentrations	concentration	NNS	I-NP
O	1812	1813	.	.	.	O

